Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients

Bo, Jiaqi; Yu, Bo; Bi, Rui; Xu, Xin; Cheng, Ya-Min; Tu, Xiaoyu; Bai, Qianming; Yang, Wentao; Shui, Ruohong

doi:10.1016/j.clbc.2023.03.002

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Changes In Her2-low Status During the Disease Coursementioning

confidence: 99%

“…Several studies have recently investigated the transition of HER2 status, including the HER2-low concept, in both early and advanced settings [24,[33][34][35][36][37][38][39][40][41][42][43][44][45]. The discordant rate of HER2 status between the primary tumor and residual disease after neoadjuvant chemotherapy was 21.4-36.4% [24,[33][34][35]42]. Similarly, when evaluating the HER2 status of the primary tumor and a paired recurrent lesion and/or metastatic lesion, substantial portions of tumors showed a discordant HER2 status, ranging from 27.6 to 38% [36][37][38][39][40][41][43][44][45].…”

Section: Changes In Her2-low Status During the Disease Coursementioning

confidence: 99%

See 1 more Smart Citation

HER2-Low Breast Cancer: Now and in the Future

Kang,

Kim

2024

Cancer Res Treat

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease, and its subtypes are characterized by hormone receptor and human epidermal growth factor receptor 2 (HER2) expression status. "HER2-low" tumors, which exhibit a low level of HER2 expression (immunohistochemistry 1+ or 2+ without gene amplification), were conventionally considered not amenable to anti-HER2 targeting agents based on the results of a phase III trial of trastuzumab. However, this perspective is being challenged by the emergence of novel anti-HER2 antibody-drug conjugates, such as trastuzumab-deruxtecan. These innovative therapies have demonstrated remarkable efficacy against HER2-low breast cancer, shedding new light on a previously overlooked category of breast cancer. Such promising results highlight the need for in-depth investigations of the biology and prognostic implications of HER2-low tumors. In this review, we comprehensively summarize the current evidence surrounding this topic and highlight areas that warrant further exploration and research in the future.

show abstract

Section: Changes In Her2-low Status During the Disease Coursementioning

confidence: 99%

Section: Changes In Her2-low Status During the Disease Coursementioning

confidence: 99%

HER2-Low Breast Cancer: Now and in the Future

Kang,

Kim

2024

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer

Bischoff,

Espié,

Petit

2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion Statement This perspective underscores the evolution and significance of neoadjuvant therapy in breast cancer, tracing its history and efficacy in improving outcomes. It delves into the correlation between achieving complete response and long-term survival, emphasizing the predictive value of treatment response estimation. Neoadjuvant chemotherapy in HER2-positive early breast cancer, particularly with taxanes and anti-HER2 therapies, emerges as a cornerstone, offering enhanced breast conservation rates and prognostic insights. The focus on individualized care, tailored to treatment response, underscores the need for adaptive strategies. Additionally, the article discusses the ongoing debate surrounding anthracyclines' role and the benefits of dual HER2 blockade. Ultimately, advocating for a personalized approach, guided by treatment response assessment, ensures optimal outcomes in HER2-positive breast cancer management.

show abstract

Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

Kang

Lee

et al. 2023

European Journal of Cancer

View full text Add to dashboard Cite

Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients

Cited by 4 publications

References 35 publications

HER2-Low Breast Cancer: Now and in the Future

HER2-Low Breast Cancer: Now and in the Future

Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer

Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

Contact Info

Product

Resources

About